A comparison of calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD

68Citations
Citations of this article
48Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Patients with chronic kidney disease (CKD) have increased risk of fractures, yet the optimal treatment is unknown. In secondary analyses of large randomized trials, bisphosphonates have been shown to improve bone mineral density and reduce fractures. However, bisphosphonates are currently not recommended in patients with advanced kidney disease due to concern about oversuppressing bone remodeling, which may increase the risk of developing arterial calcification. In the present study we used a naturally occurring rat model of CKD with secondary hyperparathyroidism, the Cy/+ rat, and compared the efficacy of treatment with zoledronic acid, calcium given in water to simulate a phosphate binder, and the combination of calcium and zoledronic acid. Animals were treated beginning at 25 weeks of age (approximately 30% of normal renal function) and followed for 10 weeks. The results demonstrate that both zoledronic acid and calcium improved bone volume by micro-computed tomography (μCT) and both equally suppressed the mineral apposition rate, bone formation rate, and mineralizing surface of trabecular bone. In contrast, only calcium treatment with or without zoledronic acid improved cortical porosity and cortical biomechanical properties (ultimate load and stiffness) and lowered parathyroid hormone (PTH). However, only calcium treatment led to the adverse effects of increased arterial calcification and fibroblast growth factor 23 (FGF23). These results suggest zoledronic acid may improve trabecular bone volume in CKD in the presence of secondary hyperparathyroidism, but does not benefit extraskeletal calcification or cortical biomechanical properties. Calcium effectively reduces PTH and benefits both cortical and trabecular bone yet increases the degree of extra skeletal calcification. © 2014 American Society for Bone and Mineral Research.

References Powered by Scopus

Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee

5019Citations
N/AReaders
Get full text

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

2553Citations
N/AReaders
Get full text

FGF23 induces left ventricular hypertrophy

1707Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial

266Citations
N/AReaders
Get full text

Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy

105Citations
N/AReaders
Get full text

The use of fibroblast growth factor 23 testing in patients with kidney disease

54Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Moe, S. M., Chen, N. X., Newman, C. L., Gattone, V. H., Organ, J. M., Chen, X., & Allen, M. R. (2014). A comparison of calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD. Journal of Bone and Mineral Research, 29(4), 902–910. https://doi.org/10.1002/jbmr.2089

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 21

58%

Researcher 8

22%

Professor / Associate Prof. 7

19%

Readers' Discipline

Tooltip

Medicine and Dentistry 15

58%

Materials Science 4

15%

Biochemistry, Genetics and Molecular Bi... 4

15%

Engineering 3

12%

Save time finding and organizing research with Mendeley

Sign up for free